Viking Therapeutics Presents Phase 3 VK2735 Obesity Trial Update
Viking Therapeutics presented an update on its Phase 3 VK2735 obesity trial. The supplied body is truncated after “expects dat”.
Related stories
Grand Pharmaceutical Says CBT-001 Meets Primary Endpoint in Phase III Trial
Grand Pharmaceutical said CBT-001 met the primary endpoint in a Phase III trial for pterygium.
M impact | EQUITY | Nov 05, 2026, 12:12 AM UTC
Lotte Energy Materials Swings to Q3 Net Profit of KRW 70.4 Billion
M impact | EQUITY | Nov 05, 2026, 12:12 AM UTC
Advantest shares extend decline, falling as much as 8.8%
M impact | EQUITY | Nov 05, 2026, 12:12 AM UTC
Citi Employee Killed in Shooting at Florida Office; Suspect Dead
M impact | EQUITY | Nov 05, 2026, 12:12 AM UTC
Oceanagold Reports Quarterly Revenue of $149.1 Million
M impact | EQUITY | Nov 05, 2026, 12:11 AM UTC
Kakao Plans KRW 150 Billion Share Cancellation
Kakao plans to cancel shares worth KRW 150 billion.
M impact | EQUITY | Nov 05, 2026, 12:10 AM UTC